Applications

1821 – Testing for Chromogranin A in patients with neuroendocrine neoplasms

Find out about the service or technology in application 1821 and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input, and the outcome of the application when the MSAC process is complete.

  • Status Pre-assessment
  • Type New application
  • Pre-PASC consultation Open
  • Pre-MSAC consultation Not yet started
  • Outcome Pending

Application details

Applicant

The Royal College of Pathologists of Australasia

Reason for application

New Medicare Benefits Schedule item

Service or technology in this application

Chromogranin A (CgA) testing is a blood test used to help monitor people with metastatic neuroendocrine tumours (NETs) over time. It is used alongside scans, medical reviews, and other tests. The test is a simple and minimally invasive way to look for changes that suggest the cancer is growing or responding to treatment. This helps doctors decide when closer follow-up, more scans, or changes in care are needed.

Medical condition this application addresses

Metastatic neuroendocrine tumours are cancers that start in neuroendocrine cells, which are found throughout the body, most often in the digestive system, pancreas, and lungs. When the cancer is metastatic, it has spread from where it began. People with this condition usually need long-term monitoring to check if the cancer is stable or worsening, and whether treatment is still working.

Consultation survey and deadlines

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the application is addressing.   

Before providing your input, please read our Privacy Notice for MSAC consultation input to ensure you are comfortable with how we will use your input.  

The following consultation deadlines apply:

  • Pre-PASC consultation deadline: Friday 10 July 2026 11:59pm AEST
  • Pre-MSAC consultation deadline: To be confirmed

For other ways to provide input, see how to have your say.

Find out more about consultation.

Meetings to consider this application

This application will be considered at the following meetings:

  • PASC meeting: 13 to 14 August 2026
  • ESC meeting: To be confirmed
  • MSAC meeting: To be confirmed

Find out more about our meetings.

Outcome details

The outcome of this application is pending.

More information

Find out more about: